



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/494,242	01/31/2000	Reid W. Von Borstel	1331-301	3187

7590

06/26/2002

Nixon and Vanderhye PC
8th Floor
1100 North Glebe Road
Arlington, VA 22201

EXAMINER

OWENS JR, HOWARD V

ART UNIT

PAPER NUMBER

1623

DATE MAILED: 06/26/2002

7

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application N . 09/494,242	Applicant(s) VON BORSTEL ET AL.	
	Examin r Howard V Owens	Art Unit 1623	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) ☐ Responsive to communication(s) filed on _____.

2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.

3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) ☒ Claim(s) 1-47 is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5) ☐ Claim(s) _____ is/are allowed.

6) ☐ Claim(s) _____ is/are rejected.

7) ☐ Claim(s) _____ is/are objected to.

8) ☒ Claim(s) 1-47 are subject to restriction and/or election requirement.

Application Papers

9) ☐ The specification is objected to by the Examiner.

10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.

If approved, corrected drawings are required in reply to this Office action.

12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) ☐ All b) ☐ Some * c) ☐ None of:

1. ☐ Certified copies of the priority documents have been received.

2. ☐ Certified copies of the priority documents have been received in Application No. _____.

3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).

a) ☐ The translation of the foreign language provisional application has been received.

15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)

2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____

4) ☐ Interview Summary (PTO-413) Paper No(s). _____

5) ☐ Notice of Informal Patent Application (PTO-152)

6) ☐ Other:

DETAILED ACTION

Election/Restrictions

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-4 and 17, 19-28 drawn to purine compounds/compositions, classified in class 536, subclass 27.21.
 - II. Claims 5-16 drawn to pyrimidine compounds/compositions classified in class 536, subclass 28.1.
 - III. Claims 13-16, 18 drawn to pyrimidine/purine compositions classified in class 536, subclass 27.1.
 - IV. Claims 29, 30, 45 - 47, drawn to a method of enhancing delivery of deoxyribonucleosides, classified in class 514, subclass 45.
 - V. Claims 32-35, drawn to a method for treating or preventing radiation-induced cellular damage, classified in class 514, subclass 42.
 - VI. Claim 31, drawn to a method for treating cardiac insufficiency, classified in class 514, subclass 42.
 - VII. Claims 38-44, drawn to a method for enhancing the healing of damaged tissue classified in class 514, subclass 42.

The inventions are distinct, each from the other because of the following reasons:

2. Inventions I and II represent independent compounds wherein the search for either purine or pyrimidine compounds represents a divergent class/subclass field of search.

Art Unit: 1623

3. Inventions I, II and III represent independent wherein the search for either purine or pyrimidine compounds would not encompass a broader search for a composition containing both purine and pyrimidine compounds.

4. Inventions III and IV - VII are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the deoxynucleoside compound/composition can be used in the divergent methods of treatment set forth in inventions IV-VII.

5. Inventions IV - VII are drawn to distinct methods of using the same composition. The method of enhancing damaged tissue as set forth in Group VII would require a search broader in scope than those for IV or VI since the damage in this group is not limited to radiation induced damage. The method of Group VI is drawn to treating cardiac insufficiency which would require a divergent search from the radiation induced damage of Group IV.

6. Should applicant elect any one of the methods of Groups IV-VII, the compound or composition from which it depends will also be examined.

7. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

8. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Art Unit: 1623

9. Claims 16 and 19 are generic to a plurality of disclosed patentably distinct species comprising:

- Species 1 NAC, DDC, cysteamine, 2-mercaptoethanol, mercaptoethylamine, dithiothreitol, 2-mercaptoethanesulfonic acid, WR-2721, WR-1065.
- Species 2 nicotinamine, 5-hydroxytryptamine, 2-beta-aminoethyl-isothiuronium-Br-Hbr.
- Species 3 GLP/B04, GLP/B05, OK-432, Biostim, PSK, Lentinan, Schizophyllan, Rhodexman, Levan, Mannozyim.
- Species 4 MVE-2, MNR, MMZ, IL-1, TNF, thymic factor TF-5.
- Species 5 glutathione, glutathione peroxidase, glutathione reductase, glutathione transferase, superoxide dismutase, catalase.
- Species 6 selenium, CdCl₂, MnCl₂, Zn acetate, Vitamin A, beta carotene, tocopherol.
- Species 7 prostaglandins
- Species 8 methylene blue, PABA

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species, even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

10. A telephone call was made to Leonard Mitchard to request an oral election to the above restriction requirement, but did not result in an election being made.


Art Unit: 1623

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Howard Owens whose telephone number is (703) 306-4538. The examiner can normally be reached on Mon.-Fri. from 8:30 a.m. to 5 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the Primary Examiner signing this action, James O. Wilson can be reached on (703) 308-4624. The fax phone number for this Group is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-1235.



JAMES O. WILSON
PRIMARY EXAMINER
Group 1600